At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
EB-001 injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
In Brief
A Phase 2 clinical trial evaluating EB-001 injection and Placebo injection for Glabellar Frown Lines (GL). Completed, enrolled 42 participants across 2 sites.
Detailed Summary
To evaluate the safety and efficacy of EB-001 compared to placebo in subjects with glabellar frown lines (GL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines (GL)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartDec 2016
Primary CompletionJul 2017
TodayJul 2026
First PostedOct 20, 2016
Enrollment StartDec 1, 2016
Primary CompletionJul 12, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 9.7 years ago
Interventions
EB-001 injectiondrug
Placebo injectiondrug